Skip to content

TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery

TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03539354
Acronym
TerminationAF
Enrollment
60
Registered
2018-05-29
Start date
2018-07-01
Completion date
2020-05-31
Last updated
2018-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Coronary Artery Disease

Keywords

Atrial fibrillation, Spinal cord stimulatoin, Coronary artery bypass grafting

Brief summary

To compare of atrial arrhythmia incidence in patients with coronary artery disease and atrial fibrillation history, undergoing either coronary artery bypass grafting plus temporary spinal cord stimulation or coronary artery bypass grafting alone

Detailed description

The study includes 60 patients. Patients are randomized into 2 groups: coronary artery bypass grafting plus b-blocker treatment (according to guidelines; group I) and coronary artery bypass grafting plus b-blocker treatment (according to guidelines) plus temporary spinal cord stimulation (group 2). Temporary spinal cord stimulation is performed for 3 days before surgery and 7 days after coronary artery bypass grafting. Continuous ECG during intensive care unit stay, daily ECG and 24-h Holter monitor recordings at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit until 30 days after coronary artery bypass grafting. Rhythm status and clinical outcome assessment at 12 month follow up

Interventions

DEVICETemporary spinal cord stimulation

Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.

PROCEDURECoronary artery bypass grafting

Standart coronary artery bypass grafting procedure.

DRUGB-blockers

Standart b-blocker therapy will be administered in each group for AF prophylactics

Sponsors

Meshalkin Research Institute of Pathology of Circulation
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* age 18-80 years; * indications for coronary artery bypass grafting according to guidelines; * pre-operative history of paroxysmal atrial fibrillation; * absent of contraindications for spinal cord stimulation; * signed inform consent.

Exclusion criteria

* previous heart surgery or atrial fibrillation ablation procedure; * emergency coronary artery bypass grafting; * left ventricle ejection fraction \<35%; * unstable angina or heart failure; * persistent atrial fibrillation or atrial fibrillation at the time of screening; * planned Maze procedure or pulmonary vein isolation; * use of class I or III antiarrhythmic drugs within 5 elimination half-lives of the drug; * need for concomitant valve surgery; * Inability to control the device for spinal cord stimulation; * coagulopathy, immunosuppression, or other condition associated with an unacceptable surgical risk for spinal cord stimulation; * Need for therapeutic diathermy in the area of leads placement; * Need for pacemaker/ICD/CRT-D implantation; * unwillingness to participate.

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of adverse events30 daysMACE (Death, Stroke/TIA, Myocardial infarction), acute kidney injury, spinal cord injury
Occurrence of atrial tachyarrhythmias30 daysOccurrence of any atrial tachyarrhythmias including atrial fibrillation, atrial tachycardia, atrial flutter lasting ≥ 30 sec during 30 days after surgery
Occurrence of tachyarrhythmias12 monthsOccurrence of any atrial tachyarrhythmias including atrial fibrillation, atrial tachycardia, atrial flutter lasting ≥ 30 sec 30 days after surgery

Secondary

MeasureTime frameDescription
Hemodynamic parameter - Blood pressure30 daysInvasive blood pressure, pulmonary artery pressure, central venous pressure, pulmonary artery wedge pressure
Hemodynamic parameter - Heart rate30 days
Hemodynamic parameter - Cardiac index30 days
Hemodynamic parameter - Vascular resistance30 daysSystemic vascular resistance, pulmonary artery resistance
Marker of myocardial injury - high-sensitive Troponin I30 days
Inotropic score30 days
Duration of mechanical ventilation30 days
Duration of intensive care unit stay30 days
Renal-replacement therapy30 days
Acute pain assessment30 daysThe Wong-Baker Faces Pain Rating Scale
Marker of myocardial injury - CK-MB30 days
Marker of kidney injury - Creatinine30 days

Countries

Russia

Contacts

Primary ContactAlexander B Romanov, PhD
abromanov@mail.ru+79137172652

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026